Theralase Technologies Inc.

Theralase Technologies Inc.

October 26, 2011 08:00 ET

Theralase Technologies Announces Grant of Stock Options to Board Members and Officers of the Company

TORONTO, ONTARIO--(Marketwire - Oct. 26, 2011) - Theralase Technologies Inc. (TSX VENTURE:TLT) announced today that stock options totaling 1,200,000 shares, exercisable over a 5 year term at 50 cents per share, and vesting over 3 years, have been granted to Members of the Board of Directors and Officers of the Company, under the Company's subsisting 2004 Stock Option Plan.

About Theralase Technologies Inc.:

Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound healing. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination.

For further information please visit, regulatory filings may be viewed by visiting

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

Contact Information